Cybin Gets Approval for Phase 2 Trial
Cybin Inc., a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, announced on December 1, 2021 that the U.S. Food and Drug Administration (“FDA”) has authorized a Phase 2 clinical trial evaluating psychedelic-assisted psychotherapy with psilocybin for healthcare workers experiencing COVID-related distress. The trial will be conducted at the University of Washington and will aim…